Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
NCT07267078
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Biliary Tract Cancer
Interventions
DRUG:
Tuvonralimab/Iparomlimab combination with GEMOX chemotherapy
Sponsor
Peking Union Medical College Hospital